NICE recommends GLP-1 receptor agonists in specific circumstances, such as when metformin is contraindicated or not tolerated, or as an add-on therapy
Which peptides are commonly used for hormonal balance
12 Many people experience these effects within one to two weeks
Based on the current stage of clinical development and estimated trial completion dates registered on ClinicalTrials.gov, a realistic earliest possible timeline might be considered as follows: 20252026: Completion of key phase 3 TRIUMPH trial data 20262027: Potential regulatory submission to the MHRA (and FDA/EMA in parallel) 20272028: Possible MHRA marketing authorisation, subject to satisfactory review 2028 onwards: NICE technology appraisal and potential NHS commissioning decision These timelines are speculative and depend on multiple variables, including trial outcomes, the completeness of the regulatory submission, MHRA review timelines, and NICE deliberations
Quality assurance : Manufactured under strict quality control measures to guarantee sterility and safety
Stages in the development of Parkinsons disease-related pathology